Joining Signature, CMDX and Others, Affy Sets Sights on $500M Cyto Testing Market

Affy’s cytogenetic-testing chips, dubbed Cytogenetic Solution, are officially intended for research use only, but a company official said that they are also being targeted to users that offer laboratory-developed tests under the guidelines of the Clinical Laboratory Improvement Acts.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories